| INTRODUCTION
Vedolizumab (VDZ) potentially provides gut-specific immunosuppression. It recognises and binds to a4b7 integrin, a glycoprotein expressed on circulating B and T lymphocytes, inhibiting selective trafficking of gut-homing CD4+ T lymphocytes through addressin cell adhesion molecule 1 (MaDCAM-1).
1-6 Integrated analysis of registration randomised controlled trials reported by Colombel et al. indicated no greater increase in adverse events or serious adverse events compared to patients treated with placebo, but is this borne out in real-life practice? 7, [8] [9] [10] [11] [12] [13] Patients enrolled in randomised trials may not be representative which limits the generalisability of safety findings to the practicing physician in the "real world". 14 Questions related to safety persist around the mechanism of action and potential complications, including; enteric infections, anastomotic healing after surgery, immunosurveillance for malignancy and neonatal safety in pregnancy in an uncontrolled nonclinical trial environment. By
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reviewing the data available from post-marketing studies, we assess whether there are any safety signals or differences from the conclu- label extension studies), and nine cohort studies that reported safety outcomes for VDZ. [15] [16] [17] [18] [19] [20] [21] [22] [23] Two case reports of interest were included. 24, 25 We compare the safety profile established in pooled integrated analysis of all registration studies to those reported in subsequent post-marketing cohort studies in the literature to date to assess the "real world" safety profile of VDZ.
| Registration studies
Six registration studies were used to assess safety of patients exposed to VDZ (see table 1 ). [8] [9] [10] [11] [12] [13] The six studies consisted of four phase 3 trials including GEMINI 1, 2 and 3 (randomised controlled trials) and the GEMINI long-term study (open label) as well as two phase 2 trials. The phase 2 trials included the initial dose-ranging study; C13002 (placebo-controlled) and the corresponding long term safety extension of the study, C13004 (open-label study). Integrating all trials data creates a total safety population of 2932 patients. Colombel et al. pooled data from the placebo-controlled trials and long-term extension studies, of which 2830 of these patients were exposed to at least one dose of VDZ with a combined total of 4811 patient years (PYs). The median exposure for ulcerative colitis (UC) patients was 378 days (range: 1-1977) and 338 for Crohn's disease (CD) (range: 1-1927). 7 The placebo cohort is constructed using the phase 3 randomised control trials of which 504 patients received placebo contributing a total of 214 PYs of placebo exposure. Pooled, integrated analysis from Colombel is used as the comparator for the subsequent real-world cohort studies identified and summarised in this review.
| Cohort studies
We defined "post marketing" studies as any study published after the FDA approved a licence for VDZ in May 2014 and "cohort studies" as those designed to evaluate safety of patients exposed to VDZ, either prospectively or retrospectively. Using these definitions, six studies have reported safety outcomes of VDZ-exposed patients (Table 1) . [15] [16] [17] [18] [19] [20] These studies will henceforth be referred to collectively as the "post-marketing cohort studies". Two deaths were reported in post-marketing studies. One in a 72-year-old woman with CD who developed cytomegalovirus colitis after 14 weeks of VDZ and steroids. 19 She was commenced on oral ganciclovir and continued VDZ before being diagnosed with lymphoma. The second occurred in a 39 year old with no comorbid conditions. 16 She had complex disease with perianal fistulae, small bowel strictures, enteral fistulae and abscess formation. She had failed to respond to multiple medical therapies and had an extensive surgical history including a diverting ostomy. She underwent a further resection and had an anastomotic leak, dying 72 hours later.
13/2830 deaths occurred in the GEMINI studies. 7 Comparison through network meta-analysis of randomised-controlled trials (RCTs) has been performed for infliximab, adalimumab, golimumab and VDZ to assess safety profile. 26 This is a method for performing indirect comparisons between therapeutic options, in the absence of head-to-head trials. No significant differences were observed (Table 4) , nor did analysis of individual adverse events.
Supporting the findings from RCTs, cumulative real-world data on VDZ have not revealed any difference in non-infectious adverse events compared to RCTs.
| VEDOLIZUMAB AND INFECTION
Data from phase 2 and 3 trials report fewer than 1% of patients discontinued VDZ due to infection. 7 Adjusted for exposure, the incidence of upper respiratory infection (60% of all infections) was 28.6/100 patient years (PYs) for VDZ compared to 34.7/100 PYs for placebo. All other infections, including abdominal, gastrointestinal and lower respiratory tract infections occurred with similar incidence between VDZ and placebo (see Table 5 ).
T A B L E 2 Exposure-adjusted incidence rates of adverse events in the safety population of registration studies 
Acute generalised exanthematous pustulosis
to May 2016) demonstrated 40 serious and 68 nonserious
LRTIs in 46, 978 patient-years of VDZ therapy. Fifty-four of these events were pneumonia occurring at an incidence of 1-report/ 1000 years of therapy. 30 (Table 6) Safety data from real-world cohort studies are reassuring (Table 7 ). The total reported infectious complication rate across all cohort studies was 7.8% (n=82/1049). Two case reports of atypical infections while on VDZ therapy include one of Pseudomonas stutzeri meningitis in a 19-year-old woman with ileocolonic CD refractory to certolizumab, azathioprine and budesonide who received VDZ 6 weeks after her last dose of certolizumab. 24 The other was of Histoplasmosis in a 40-year-old woman, also with ileocolonic CD. 19 She presented with sepsis after her second dose of VDZ, 7 weeks after the last adalimumab dose and was on concomitant therapy with subcutaneous methotrexate 25 mg weekly.
| VE DOLIZUMAB INFUSION REACTIONS
Safety analysis of the randomised controlled trials included 2830 patients with exposure to at least one dose of VDZ and a median exposure of 378 days. Fewer than 5% patients experienced an infusion related reaction (IRR), defined as an adverse event within a day of the infusion. 7 Preliminary data from 2243 patients enrolled in the VDZ extension study (GEMINI Long Term Study (LTS)) report 87 patients (4%) had an IRR. Nausea (n=14) and headache (n=10) were the most common. In twelve patients (<1%), the infusion was interrupted or resulted in incomplete dosing because of an IRR and three developed anaphylactoid reactions: one with dyspnoea, bronchospasm and urticaria; another with rash, vomiting and a swollen tongue; and a third had throat tightness and nausea despite prophylactic hydrocortisone.
Experience from cohort studies is similar: the rate of IRR's was <2% (14/837 patients). One had an anaphylactic reaction and 2/837 patients stopped VDZ due to the severity of an IRR (please see supplementary material for IRR rate per cohort study).
| VEDOLIZUMAB AND JC VIRUS/ PROGR ESSIVE MULTIFOCAL LEUCOENCEPH ALOPATHY (PML)
The background to potential concern relates to the original antiintegrin agent, natalizumab. 566 cases of PML have occurred in over 138 000 natalizumab-exposed patients, thought to be due to 34 In patients who experienced an infusion related reaction, 5% (3/61) had two or more consecutive AVA positive tests. In the combined intention-totreat and non intention-to-treat VDZ groups, AVAs occurred in 3%
(5/161) taking concomitant immunomodulators and 4% (51/1273) in those without. 35 However, the assay used in these trials had relatively low sensitivity to detect anti-drug antibodies in the presence of detectable drug concentrations, and results of pharmacokinetic studies with drug resistant assays indicate that clinical trials are likely underreporting true drug immunogenicity incidence rates for VDZ. 36 Notably, the proportion of patients with AVAs in the GEMINI study Adjusted comparisons between anti-TNF therapy and VDZ using data from registration trials and placebo as the common comparator did not reach significance (OR: 0.87; 95% CI: 0.26-2.88). 38 While encouraging, these data overall are insufficient to draw firm conclusions about the risk of malignancy on VDZ. A reduction in immunosurveillance as a consequence of leucocyte inhibition remains a theoretical concern for GI malignancies; so long-term safety registries are needed.
| VEDOLIZUMAB AND PE RIOPE RATIVE COMPLICATIONS
By inhibiting the migration of leucocytes to sites of inflammation or repair in the gastrointestinal tract, VDZ might hypothetically impair wound healing and risk anastomotic leak or infective complications. 39 Leucocytes are intimately involved in the three phases of wound healing: inflammation, tissue formation and tissue remodelling. 40 The GEMINI trials did not examine surgical outcomes. There are three retrospective, single-centre cohort studies (Table 1) on patients who had received at least one infusion of VDZ within 12 weeks prior to surgery.
21-23
The largest cohort from the Mayo clinic attempted to compare post-operative complications after VDZ exposure with biologic-na€ ıve and anti-TNF-exposed groups (Table 9) . 21 Small bowel resection (39%), ileocolic resection (44%) and colectomy (28%) were the most common operations performed among all groups. A total of 207 (53%) patients had an anastomosis performed at surgery, including 35/94 in the VDZ group. Pre-operative treatment with VDZ was associated with an increased post-operative complication rate ( on 27 patients (27 intra-abdominal, 9 perianal) with an overall complication rate of 53%, infectious complications in 44% and anastomotic leak rate in 2/13 (15%). 22 Two deaths were reported, secondary to culture-negative sepsis, following abdominal surgery.
The third study on 15 patients undergoing intra-abdominal surgery reported only two post-operative complications (a stitch abscess and ileus requiring hospital re-admission). 23 Although these are preliminary data, it does not compare favourably to meta-analyses of perioperative anti-TNF therapy, which reported post-operative infectious complications in 15%-17%. [41] [42] [43] Caution must be exercised in over-interpreting these data due to the retrospective nature of studies; nonetheless, this signal requires further study, ideally in prospective studies, with propensity matching and adjudication of endpoints.
| VEDOLIZUMAB IN THE ELDERLY OR YOUN G
Systemic immunosuppression poses a greater risk for those at the extremes of age. A young person diagnosed with IBD, faces the possibility of lifelong immunosuppression. The absolute risk of hepatosplenic T-cell lymphoma after thiopurine therapy with or without anti-TNF may be very small, but is a genuine concern for the young patient. 44 For the elderly, immunosenescence increases the risk of systemic immunosuppression. VDZ particularly appeals 
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Eye and eyelid in such patients at risk, through avoidance of systemic immunosuppression.
Post hoc analyses of the GEMINI 1 and 2 trials indicate a good safety profile in older (age 55 years) and younger (age <35 years)
patients. There were no significant differences in adverse events or infections amongst the age groups (Table 9) . 45, 46 A single, multicentre, retrospective cohort study has reported on VDZ initiated over age 60 (mean 67.1) in 29 patients (10 UC and 19 CD). 47 Median treatment duration was 30 weeks. Three patients (10%) experienced adverse events including pneumonia, worsening gastrointestinal symptoms and flu-like symptoms. The early signal is promising for the safety of VDZ in the elderly.
A single-centre, prospective observational cohort study from The
Children's Hospital of Philadelphia followed 21 young people (16 CD, 3 UC, 2 IBDU), aged 13-21 years (age: 13-18, n=15; age: 19-21, n=6). 48 Adverse events were similar to adult populations, with upper respiratory tract infections the most common (Table S2) .
Nevertheless, 8/21 (38%) experienced 12 serious adverse events that required hospitalisation and two patients discontinued VDZ.
Two patients required surgery secondary to disease progression and one developed obstructing nephrolithiasis with associated pyonephritis. Interestingly, three patients developed new extraintestinal manifestations. Two patients developed erythema nodosum and one developed bowel-associated dermatosis-arthritis syndrome. Caution is necessary to avoid over-interpreting these data: all patients had severe disease; all were refractory to anti-TNF therapy, steroid dependent and without alternative medical options apart from surgery. On the other hand, Cox proportional hazards modelling of the 6 VDZ registration trials identified young age as a factor independently associated with serious infection in patients with CD. 7 There has been another retrospective cohort study of 52 children with CD (58%) or UC (42%), who had almost all failed anti-TNF therapy, median age 14.9 (range: 7-17) years, followed up for 30 weeks. 49 No serious adverse events were reported. Careful counselling of women of child-bearing age who are treated with VDZ is needed: there is no safety signal from reports to date, but concerns should not be ignored. An FDA observational pregnancy registry has been initiated.
| VEDOLIZUMAB AND VACCINES
Patients with IBD are at increased risk of infections, secondary to the immune dysregulation of underlying disease and immunosuppressive therapy. Some of the infections are preventable, but vaccination rates amongst patients with IBD remain low: 28% for influenza vaccination and 12% for hepatitis B vaccine. [53] [54] [55] [56] [57] In a well-designed demonstration of VDZ gut selectivity, a double-blinded RCT administered parenteral hepatitis B vaccine and oral cholera vaccine to patients who received VDZ or placebo. 58 The antibody response to the oral antigen was significantly attenuated, but the response to parenterally administered antigen was unaffected, consistent with a gut selective mechanism of action. It means that oral or mucosal administered vaccines cannot be expected to work during VDZ therapy, although parenteral vaccination will be unaffected. It is also conceivable that live parenteral vaccines might be safe in patients receiving VDZ. The FDA label states that patients should only receive live vaccines if the benefits outweigh the risks. 50 One case has been reported of the safe and successful administration of live measles, mumps and rubella vaccine to a patient receiving VDZ. 25 An adequate measles antibody index response was demonstrated (from 0.7 (negative) to 2.06 (positive)). Further study is warranted. Dr Bye has no disclosures.
| CONCLUSIONS

AUTHORSHIP
Guarantor of the article: Prof. S. Travis.
Author contributions: Dr Bye wrote the initial draft that was then extensively edited by Professors Travis and Jairath.
All authors approved the final version of the manuscript.
R E F E R E N C E S
1. Soler-Ferran D, Champan T, Yang LL ., et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7
